12:00 AM
 | 
Oct 29, 2012
 |  BC Week In Review  |  Company News  |  Deals

Alnylam, Sanofi deal

Alnylam granted Sanofi's Genzyme Corp. unit exclusive rights in Japan and other Asia-Pacific countries to develop and commercialize RNAi therapeutics for transthyretin (TTR). The deal includes two products for TTR-mediated amyloidosis: IV ALN-TTR02, in Phase II testing; and subcutaneous ALN-TTRsc, in preclinical testing. Alnylam plans to submit an IND to FDA by year end to begin Phase I testing of ALN-TTRsc. An international Phase III trial of ALN-TTR02 is slated to start...

Read the full 379 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >